Lidocaine transdermal patch - Scilex Pharmaceuticals

Drug Profile

Lidocaine transdermal patch - Scilex Pharmaceuticals

Alternative Names: Lidocaine 1.8% patch - Scilex Pharmaceuticals; ZTlido

Latest Information Update: 05 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Scilex Pharmaceuticals
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Postherpetic neuralgia

Most Recent Events

  • 28 Feb 2018 Registered for Postherpetic neuralgia in USA (Transdermal)
  • 28 Feb 2018 Scilex Pharmaceuticals intends to launch Lidocaine transdermal patch (ZTlidoTM) in the US, in 2018
  • 28 Feb 2018 Efficacy data from a clinical adhesion study in healthy volunteers released by Sorrento Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top